These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 31640855)

  • 1. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
    Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
    Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
    Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
    Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells.
    Castro-Gamero AM; Borges KS; da Silva Silveira V; Lira RC; de Paula Gomes Queiroz R; Valera FC; Scrideli CA; Umezawa K; Tone LG
    Anticancer Drugs; 2012 Jul; 23(6):638-50. PubMed ID: 22382389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
    Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
    Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
    He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
    Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance.
    Avnet S; Lemma S; Cortini M; Pellegrini P; Perut F; Zini N; Kusuzaki K; Chano T; Grisendi G; Dominici M; De Milito A; Baldini N
    Oncotarget; 2016 Sep; 7(39):63408-63423. PubMed ID: 27566564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
    Huang H; Wang L; Li M; Wang X; Zhang L
    World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
    Wu DP; Yan XB; Liu LG; Tian C; Han K; Zhang H; Min DL
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4022-4031. PubMed ID: 29028101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascorbate sensitizes human osteosarcoma cells to the cytostatic effects of cisplatin.
    Oka N; Komuro A; Amano H; Dash S; Honda M; Ota K; Nishimura S; Ueda T; Akagi M; Okada H
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00632. PubMed ID: 32725721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1.
    Kun-Peng Z; Xiao-Long M; Chun-Lin Z
    Int J Biol Sci; 2018; 14(3):321-330. PubMed ID: 29559849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.
    Zhou Y; Huang Z; Wu S; Zang X; Liu M; Shi J
    J Exp Clin Cancer Res; 2014 Jan; 33(1):12. PubMed ID: 24468065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1® can Overcome Drug Resistance in Osteosarcoma.
    Fanelli M; Hattinger CM; Vella S; Tavanti E; Michelacci F; Gudeman B; Barnett D; Picci P; Serra M
    Curr Cancer Drug Targets; 2016; 16(3):261-74. PubMed ID: 26548759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4 blockade sensitizes osteosarcoma to doxorubicin by inducing autophagic cell death via PI3K‑Akt‑mTOR pathway inhibition.
    Liao YX; Lv JY; Zhou ZF; Xu TY; Yang D; Gao QM; Fan L; Li GD; Yu HY; Liu KY
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34080667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome Inhibitor MG132 Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells and Inhibits Tumor Growth.
    Sun F; Zhang Y; Xu L; Li S; Chen X; Zhang L; Wu Y; Li J
    Oncol Res; 2018 May; 26(4):655-664. PubMed ID: 29191257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
    Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
    BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERRα contributes to HDAC6-induced chemoresistance of osteosarcoma cells.
    He Q; Yu C; Li Y; Hao P; Mai H; Guo R; Zhong G; Zhang K; Wong C; Chen Q; Chen Y
    Cell Biol Toxicol; 2023 Jun; 39(3):813-825. PubMed ID: 34524571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of miR-377 contributes to cisplatin resistance by targeting XIAP in osteosarcoma.
    Liu XG; Xu J; Li F; Li MJ; Hu T
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1249-1257. PubMed ID: 29565481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
    Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-184 Modulates Doxorubicin Resistance in Osteosarcoma Cells by Targeting BCL2L1.
    Lin BC; Huang D; Yu CQ; Mou Y; Liu YH; Zhang DW; Shi FJ
    Med Sci Monit; 2016 May; 22():1761-5. PubMed ID: 27222034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
    Huang Z; Huang Y; He H; Ni J
    Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.